Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study.

Alessandro D. Santin,Takefumi Komiya,David M. Goldenberg,Robert M. Sharkey,Quan Hong,William A. Wegener,Trishna Goswami,Aditya Bardia

Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study.

2020

Alessandro D. Santin
Takefumi Komiya
David M. Goldenberg
Robert M. Sharkey
Quan Hong
William A. Wegener
Trishna Goswami
Aditya Bardia

6081Background: Unselected pts with EC who progressed on prior chemotherapy have a poor prognosis with limited treatment options. SG is a novel antibody-drug conjugate that targets Trop-2, a cell s...

Keywords:

Metastatic endometrial cancer
Oncology
Sacituzumab govitecan
Internal medicine
Medicine
previously treated
Pathology
in patient
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations